n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
OTTAWA, ON, March 19, 2024 /PRNewswire/ — Innovative Medicines Canada (IMC) will announce that Dr. Bettina Hamelin has been appointed its new president, effective April 8, 2024.
Dr. Hamelin, PharmD, EMBA, comes to IMC with more than 30 years of experience in academia, industry, and nonprofits. Most recently, she served as President and CEO of Ontario Genomics, a not-for-profit organization committed to catalyzing and supporting the progression of genomics and bioengineering-based responses in key sectors of the economy.
“We are thrilled to have Dr. Hamelin lead our industry system at a time when transforming healthcare is a priority for Canadians,” said Brigitte Nolet, Chair of the Board of Directors of IMC. “Dr. Hamelin has spent the last six years leading advocacy efforts on behalf of biotechnology organizations that include long-term innovation. Her experience and in-depth knowledge in this field make her a natural choice to collaborate with fitness stakeholders to ensure Canada is in a position to embrace the next generation of pharmaceutical inventions that will be the overall fitness of Canadians.
Prior to joining Ontario Genomics, Dr. Hamelin was Vice President of the Research Partnerships Branch at the Engineering and Natural Sciences Research Council of Canada (NSERC), where she was guilty of fostering public-private sector collaboration and generational movement by connecting Canadian studies. companies with Canadian and global innovation partners. In the past she has also held positions of increasing responsibility in the pharmaceutical and biogeneration industries, adding leadership positions at BioChem Pharma and Pfizer, in addition to 10 years of experience in educational studies as a full professor at the Université Lava.
“It is an honour to champion an industry that continually harnesses the power of science for the health and well-being of Canadians,” said Bettina Hamelin, new president of Innovative Medicines Canada. “The cutting-edge pharmaceutical industry accomplishes this not only through offering new remedies and vaccines, but also by contributing to our economy, investing in research and development, supporting high-value jobs, and sponsoring the majority of clinical trials in Canada.
Dr. Hamelin is an active volunteer in the broader innovation community, and serves on the Board of Directors of the Center for Trial Commercialization and Development and IRICoR, a center of excellence in commercialization and specializing in drug discovery. He also chairs the National Center for Engineering-Biology. Steering Committee, serves on the Steering Committee of the Ontario COVID-19 Genomics Network, participates in several advisory committees, and mentors Creative Destruction Lab, a global seed program for early-stage scientific projects.
Dr. Hamelin will succeed David Renwick, who has served as interim president of Innovative Medicines Canada since November 2023. We would like to thank Mr. Renwick for his valuable contributions to the organization of his mandate.
About Innovative Medicines Canada
Innovative Medicines Canada is the national agreement representing the voice of Canada’s cutting-edge pharmaceutical industry. The agreement advocates for policies that enable the discovery, progression and delivery of cutting-edge medicines and vaccines for the lives of all Canadians and supports its members’ commitment to being a valued partner in Canada’s health care system. The deal represents 48 corporations investing about $1. 4 billion in R&D.
SOURCE Innovative Medicines Canada
Watch the content to download media: http://www. newswire. ca/en/releases/archive/March2024/19/c2456. html